$NTRA · Natera, Inc.
Natera filed its 10-Q for the quarter ended September 30, 2026. Total revenue grew 34.1% YoY to $794M, driven by product revenue of $790M (+33.9%). Net loss narrowed 31.6% to $59.9M, or $0.42 per share, from $87.5M ($0.64) a year earlier. Operating loss improved to $68.3M from $97.6M, though R&D expense jumped 39.8% to $242.4M and SG&A rose 8.1% to $333.7M.
- Total revenue rose 34.1% YoY to $794M in Q3 FY2026.
- Product revenue grew 33.9% to $790M, led by insurance carriers at $733.2M.
- Net loss narrowed 31.6% to $59.9M, or $0.42 per share.
- R&D expense jumped 39.8% YoY to $242.4M.
- Cash and equivalents stood at $1.10B as of September 30, 2026.
Extended-hours trading shows the stock down 17.25% to $301.00 vs the regular close of $363.76, despite narrowing losses and strong revenue growth — suggesting the market is reacting to something beyond the headline numbers, likely forward guidance or margin concerns.
A 34% revenue jump with narrowing losses is strong, but a 17% after-hours selloff signals investors are worried about something the headline numbers don't show.
Natera's 34% revenue growth and continued losses reflect the high-spend, high-growth profile of molecular diagnostics peers investing heavily in oncology and organ-health test expansion.
Rising R&D (+39.8%) and SG&A (+8.1%) spending outpace revenue growth in absolute terms, keeping the company unprofitable. Integration of Foresight Diagnostics and reliance on a limited number of suppliers are flagged as ongoing risks.